



ASX Announcement

26 November 2024

BCAL RECEIVES RESEARCH AND DEVELOPMENT TAX OFFSET \$2.6 MILLION

BCAL Diagnostics Limited (ASX: BDX) (BCAL or Company), an Australian-based biotechnology company developing a blood test for detection of early-stage breast cancer, is pleased to advise the receipt of its FY2024 Research and Development Tax Incentive (RDTI) tax offset in the amount of ~\$2,628,000.

BCAL is developing a blood based biomarker test for breast cancer BREASTEST™, and will in Q1 CY2025 commence phase one of the commercial launch of its first product, in partnership with the Sydney Breast Clinic.

The RDTI is an Australian Government program providing important support for biotechnology and other sectors under which companies receive a refund for eligible expenditure on research and development.

BCAL CEO, Shane Ryan, commented: *"The support of the RDTI program is essential in assisting BCAL in funding the development of BREASTEST™, with the first product about to commence our journey in making a significant contribution in women's health."*

This announcement has been approved for release to the ASX by the Board.

ENDS

Jayne Shaw
Executive Chair
Jshaw@bcaldiagnostics.com

Shayne Ryan
Chief Executive Officer
sryan@bcaldiagnostics.com

ABOUT BCAL DIAGNOSTICS

For personal use only

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating 90% specificity and 85% accuracy. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX:BDX). For more information: <https://www.bcaldiagnostics.com/>